The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2023-11-01 / Immun Inflamm Dis 2023 Nov;11(11):e1099WT1 Dendritic Cell Vaccine Therapy Improves Immune Profile and Prolongs Progression-Free Survival in End-Stage Lung Cancer
/in Dendritic Cells, International Publications, NSCLC /von 2023-10-19 / Cureus 2023 Oct;15(10):e47320Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
/in Dendritic Cells, International Publications, NSCLC /von 2023-10-04 / Cells 2023 Oct;12(19)Tumor cell vaccine combined with Newcastle disease virus promote immunotherapy of lung cancer
/in International Publications, Newcastle Disease Virus, NSCLC /von 2023-02-01 / J Med Virol 2023 Feb;95(2):e28554A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients
/in Dendritic Cells, International Publications, NSCLC /von 2022-01-01 / Integr Cancer Ther 2022;21:15347354221083968Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers
/in Dendritic Cells, International Publications, NSCLC /von 2021-12-24 / ESMO Open 2022 Feb;7(1):100334Modulation of the immune response by heterogeneous monocytes and dendritic cells in lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2021-11-24 / World J Clin Oncol 2021 Nov;12(11):966-982Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1
/in Dendritic Cells, International Publications, NSCLC /von 2021-11-02 / Cancers (Basel) 2021 Nov;13(21)Targeting CD166 lung cancer stem cells: Molecular study using murine dendritic cell vaccine
/in Dendritic Cells, International Publications, NSCLC, SCLC /von 2021-08-23 / Toxicol Appl Pharmacol 2021 Oct;429:115699IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de